Skip to content

US · DRTS · MEDICAL - EQUIPMENT & SERVICES

Alpha Tau Medical Ltd (DRTS) intrinsic value and stock valuation

$11.76as of 2026-11-21 · Mkt cap 1.2B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alpha Tau Medical Ltd DCF and intrinsic value

InvestorsCraft values DRTS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DRTS’s statements →

Alpha Tau Medical Ltd Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Equipment & Services Jerusalem, JM 9777605 alphatau.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-42.63M
20192025
Free cash flow
-$-32.76M
20192025
Total equity
$77.1M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-42.29M-$-36.04M$35.7M-$-32.14M-$-13.79M
Net income-$-42.63M-$-31.75M-$-29.16M-$-33.76M-$-27.27M
EPSd-$-529.04K-$-454.03K-$-420.29K-$-531.4K-$-672.83K
Operating cash flow-$-26.68M-$-19.78M-$-17.96M-$-23.88M-$-11.81M
Capital expenditure-$-6.08M-$-2.24M-$-6.4M-$-900K-$-2.93M
Free cash flow-$-32.76M-$-22.02M-$-24.36M-$-24.78M-$-14.74M
Total assets$106.6M$86.2M$107.4M$120.2M$42.2M
Total debt$13.7M$12.5M$13.3M$5.19M$54M
Net debt-$-2.25M-$-1.19M$620K-$-640K$30.7M
Total equity$77.1M$62.7M$84.5M$105.7M-$-34.78M
Cash and short-term investments$76.9M$59.6M$81.8M$104.5M$31.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$1.23M$1.1M$1.07M$980K$780K
Gross profit-$-1.23M-$-1.1M-$-1.07M-$-980K-$-780K
Research and development expenses$30.8M$27M$26.4M$20.9M$11.5M
Selling, general and administrative expenses$10.2M$7.92M$9.26M$11.3M$2.34M
Other expenses$0.00$0.00-$-1.07M$0.00$0.00
Operating expenses$41.1M$34.9M$34.6M$32.1M$13.8M
Cost and expenses$42.3M-$-36.04M-$-35.68M$32.1M$13.8M
Interest income$3.84M$4.28M$4.75M$1.79M$210K
Interest expense$420K$340K$40K$1.77M$13.3M
Depreciation and amortization$1.23M$1.1M$1.07M$980K$780K
Ebitda-$-41.06M-$-30.3M-$-28.03M-$-32.74M-$-13.21M
Operating income-$-42.29M-$-36.04M$35.7M-$-32.14M-$-13.79M
Total other income/expenses, net-$-220K$4.3M$6.54M-$-1.61M-$-13.47M
Income before tax-$-42.51M-$-31.74M-$-29.14M-$-33.74M-$-27.26M
Income tax expense$120K$10K$20K$20K$10K
Net income-$-42.63M-$-31.75M-$-29.16M-$-33.76M-$-27.27M
Weighted average shares outstanding$80.6M$69.9M$69.4M$63.5M$40.5M
Weighted average diluted shares outstanding$80.6M$69.9M$69.4M$63.5M$40.5M
Balance sheet
20252024202320222021
Cash and short-term investments$76.9M$59.6M$81.8M$104.5M$31.3M
Net receivables$40K$330K$20K$30K$480K
Inventory$0.00$0.00-$-20K$0.00-$-8.17M
Total current assets$78.3M$64.2M$85.8M$106.5M$32.6M
Property, plant and equipment, net$26.9M$21.5M$21.2M$13.3M$7.55M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$28.3M$22M$21.6M$13.7M$9.57M
Total assets$106.6M$86.2M$107.4M$120.2M$42.2M
Accounts payable$3.87M$3.53M$2.57M$1.42M$1.2M
Short-term debt$1.13M$2.02M$2.12M$670K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$10.5M$8.68M$7.1M$4.34M$4.41M
Long-term debt$12.6M$11.5M$12.2M$4.52M$54M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$19M$14.9M$15.8M$10.2M$72.6M
Capital lease obligations$7.37M$6.97M$7.67M$5.19M$0.00
Total liabilities$29.5M$23.5M$22.9M$14.5M$77M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-190.14M-$-147.51M-$-115.76M-$-86.6M-$-52.84M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$77.1M$62.7M$84.5M$105.7M-$-34.78M
Total investments$60.9M$45.9M$69.1M$98.7M$8.08M
Total debt$13.7M$12.5M$13.3M$5.19M$54M
Net debt-$-2.25M-$-1.19M$620K-$-640K$30.7M
Cash flow statement
20252024202320222021
Net income-$-42.63M-$-31.75M-$-29.16M-$-33.76M-$-27.27M
Depreciation and amortization$1.23M$1.1M$1.07M$980K$780K
Stock-based compensation$0.00$9.92M$7.93M$6.75M$810K
Change in working capital$2.29M$1.17M$2.49M-$-310K$580K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$340K$960K$1.14M$220K$240K
Net cash provided by operating activities-$-26.68M-$-19.78M-$-17.96M-$-23.88M-$-11.81M
Investments in property, plant and equipment-$-6.08M-$-2.24M-$-6.4M-$-900K-$-2.93M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-20.59M$20.8M$18.7M-$-89.94M$19.3M
Common stock issued$45.8M$30K$50K$3.36M$110K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$45.8M$30K$5.3M$96.9M$110K
Net change in cash-$-1M$1.17M$9.12M-$-17.17M$7.68M
Cash at end of period$16M$17M$15.8M$6.69M$23.9M
Operating cash flow-$-26.68M-$-19.78M-$-17.96M-$-23.88M-$-11.81M
Capital expenditure-$-6.08M-$-2.24M-$-6.4M-$-900K-$-2.93M
Free cash flow-$-32.76M-$-22.02M-$-24.36M-$-24.78M-$-14.74M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alpha Tau Medical Ltd

        Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

        CEO
        Uzi Sofer
        Employees
        121
        Beta
        1.17

        Explore

        Frequently asked questions

        What is the intrinsic value of Alpha Tau Medical Ltd (DRTS)?

        InvestorsCraft does not currently publish an intrinsic value for DRTS. How the IC value is calculated.

        Is DRTS undervalued?

        InvestorsCraft does not publish an undervaluation signal for DRTS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.